Von Hippel-Lindau disease (VHL): treatment
Evidence-based neurology checklist on von hippel-lindau disease (vhl): treatment: Central nervous system haemangiomas Belzutifan Surgery Retinal haemangiomas Pancreatic neuroendocrine tumours (PNETs) Renal cell cancer Phaeochromocytoma paraganglioma Endolymphatic sac tumour
Central nervous system haemangiomas
- Belzutifan
- Surgery
Retinal haemangiomas
Pancreatic neuroendocrine tumours (PNETs)
Renal cell cancer
Phaeochromocytoma paraganglioma
Endolymphatic sac tumour
References
- Daniels AB, Tirosh A, Huntoon K, et al. Guidelines for surveillance of patients with von Hippel-Lindau disease: Consensus statement of the International VHL Surveillance Guidelines Consortium and VHL Alliance. Cancer 2023 (Online ahead of print).
- Louise M Binderup M, Smerdel M, Borgwadt L, et al. von Hippel-Lindau disease: Updated guideline for diagnosis and surveillance. Eur J Med Genet 2022; 65:104538.
- Neth BJ, Webb MJ, White J, Uhm JH, Pichurin PN, Sener U. Belzutifan in adults with VHL-associated central nervous system hemangioblastoma: a single-center experience. J Neurooncol 2023 (Online ahead of print).
- Takeshima Y, Takami H, Endo T, et al. Comparison of the recurrence and surgical outcome of spinal hemangioblastoma in sporadic and Von Hippel-Lindau diseases: a subanalysis of a nationwide study by the Neurospine Society of Japan. Neurospine 2023 (Online ahead of print).
- Jones AA, Schloemer NJ, Wirostko WJ. Successful treatment of Von Hippel-Lindau (VHL) disease-associated retinal capillary hemangioblastoma (RCH) with belzutifan in a pediatric patient. Retin Cases Brief Rep 2023 (Online ahead of print).
- And 5 more. Subscribe to see the full list
